Fig. 3From: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisEfficacy Results. A: VS Risk Difference (RE model). B: CD4 difference (FE model)Back to article page